Stock Events

Cognetivity Neurosciences 

C$0.01
1
+C$0+0% Wednesday 13:30

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
29.77M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7JunExpected
Q3 2021
Q1 2022
Q2 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.08
-0.06
-0.03
-0.01
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGN.CN. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly is a major pharmaceutical company that develops drugs for neurological diseases, including Alzheimer's, which competes with CGNSF's cognitive assessment technologies.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on neurodegenerative diseases, including Alzheimer's disease treatments and diagnostics, directly competing with CGNSF's cognitive testing products.
Pfizer
PFE
Mkt Cap164.39B
Pfizer develops medications for various neurological conditions, which can be seen as alternatives to CGNSF's cognitive assessment tools.
Merck
MRK
Mkt Cap300.25B
Merck is involved in the development of treatments for Alzheimer's disease, competing in the same space as CGNSF's cognitive diagnostics.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories offers a range of healthcare solutions including diagnostics for neurological conditions, overlapping with CGNSF's market.
Sage Therapeutics
SAGE
Mkt Cap514.65M
Sage Therapeutics develops treatments for central nervous system disorders, which can be used alongside or as an alternative to CGNSF's technologies.
Novartis
NVS
Mkt Cap244.75B
Novartis provides healthcare solutions including neurological disease treatments, competing in the cognitive health space.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical division, develops treatments for neurodegenerative diseases, competing with CGNSF's cognitive assessment tools.
AC Immune SA
ACIU
Mkt Cap319.58M
AC Immune focuses on Alzheimer's disease diagnostics and therapeutics, directly competing with CGNSF's cognitive assessment technologies.

About

Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia, as well as other neurological conditions. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
Dr. Sina Habibi
Country
CA
ISIN
CA19243C1005

Listings

US
CGNSF
CN
CA
CGN.CN
F
DE
1UB.F